Fat Loss · 5mg × 10 vials
it was designed to be "HGH fat loss without the side effects", and on the side-effect promise it delivered (clean safety profile, no insulin/IGF/growth effects), but on the fat-loss promise the human evidence is weak and the Australian Phase 2b trial failed its primary endpoint.
AOD-9604 ("Anti-Obesity Drug 9604") is a 16-amino-acid synthetic fragment of human growth hormone, corresponding to residues 177-191 of the hGH C-terminus with an added N-terminal tyrosine (the modification that distinguishes it from native HGH Fragment 176-191). The tyrosine was added to improve stability and aid radiolabeling during the Australian Metabolic Pharmaceuticals development program. Mechanistically, AOD-9604 was designed to mimic the lipolytic (fat-burning) and antilipogenic (fat-storage-blocking) actions of HGH without engaging the growth, insulin resistance, or IGF-1 pathways that limit HGH dosing. In rodent models it stimulates lipolysis in adipocytes and increases beta-3 adrenergic receptor expression, theoretically activating fat oxidation pathways. Crucially, in human trials the mechanism did not translate to meaningful weight loss: AOD-9604 binds to a high-affinity but undefined receptor (not GH-R, not B3-AR directly in humans), and the human in-vivo lipolytic signal is much weaker than the rodent data predicted. In plain language: it was designed to be "HGH fat loss without the side effects", and on the side-effect promise it delivered (clean safety profile, no insulin/IGF/growth effects), but on the fat-loss promise the human evidence is weak and the Australian Phase 2b trial failed its primary endpoint.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
5 mg vial + 2 ml BAC = 2.5 mg/ml, so 250 mcg = 0.10 ml = 10 IU on a U-100 syringe. Inject SubQ into abdomen on empty stomach, wait 30+ min before food. One 5 mg vial = 20 days at this dose. One 5 mg kit (10 vials) = 200 days at 250 mcg/day, basically a full year's research at the entry dose.
500 mcg = 0.20 ml = 20 IU on a U-100 syringe (at 2.5 mg/ml). This is the dose most community users land at and the dose used in the failed Phase 2b trial. One 5 mg vial = 10 days at this dose; a 5 mg kit = 100 days. Split dosing pre-workout is anecdotal community optimization, the published trials only tested once-daily morning dosing.
1000 mcg = 0.40 ml = 40 IU on a U-100 syringe. The Phase 2b trial actually tested up to 1 mg/day and still missed its primary endpoint, so the published evidence does not support dose escalation as a path to better results. Most experienced users at this dose are running AOD as part of a stack (with HGH, CJC+Ipa, Tesa, or a GLP-1), not as a standalone.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
original lipolytic/antilipogenic characterization in rodents
Read study ↗PubMedNg FM et al, Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone, Horm Res 2000of human growth hormone, Horm Res 2000](https://pubmed.ncbi.nlm.nih.gov/11146376/) - mechanism work, Metabolic Pharmaceuticals development origin
Read study ↗PubMedStier et al, Safety and tolerability of the hexadecapeptide AOD9604 in humans, J Endocrinol Invest 2013 (PMC3979506)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3979506/) - Phase 2a safety study, confirmed clean profile but limited efficacy signal
Read study ↗PubMedNg FM et al, A novel anti-obesity peptide, AOD9604, in pre-clinical and clinical evaluationdevelopment summary including Australian Phase 2b context
Read study ↗Clinical contextMetabolic Pharmaceuticals AOD-9604 Phase 2b 12-week obesity trial press release archivePhase 2b missed primary endpoint, 536 patients, no statistically significant weight loss vs placebo at any tested dose
Read study ↗Physician commentaryPeptide Sciences AOD-9604 clinical referenceclinical profile summary; oversold marketing tone, useful as counter-reference
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Most common report: "didn't notice anything." This is the dominant signal across r/Peptides, r/PeptideArchive, and TikTok peptide reviews. Many users complete an 8-12 week cycle with no visible change.
A minority report mild appetite suppression and modest cuts to belly fat over 8-12 weeks at 500 mcg/day, usually when paired with fasted cardio and a caloric deficit. Hard to separate from the deficit itself.
Mild fatigue or "blunted energy" in the first week, usually resolves
Rare reports of mild flushing or warmth after injection
No reports of meaningful muscle loss, mood effects, or libido changes (this is the upside of the clean mechanism)
Common discontinuation reason: "not seeing results", switched to GLP-1 or HGH
Route: SubQ
Injection site: abdomen subQ, rotate sites; some users inject into adipose tissue closest to target area (no human evidence this localizes the effect, but it's the community convention)
Storage: refrigerated, ~30 days after reconstitution; unreconstituted vials stable refrigerated long term
Notes: Administered AM fasted, ideally 30+ minutes before any food or workout. Half-life is short (~30-60 min) which is why fasted timing matters: glucose/insulin in circulation blunts the lipolytic signal. Some protocols split into AM fasted + pre-workout dose. Light-sensitive after recon, keep in original vial in fridge.